Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7576 to 7590 of 9008 results

  1. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn advice

  2. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

    Withdrawn advice

  3. Episcissors-60 for guided mediolateral episiotomy (MIB33)

    This advice has been updated and replaced by NICE medical technologies guidance 47.

    Withdrawn advice

  4. AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)

    This advice has been updated and replaced by NICE medtech innovation briefing 232.

    Withdrawn advice

  5. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Withdrawn advice

  6. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  7. FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)

    This advice has been updated and replaced by NICE medtech innovation briefing 224.

    Withdrawn advice

  8. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  9. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

    Withdrawn advice

  10. Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)

    NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.

    Withdrawn advice

  11. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  12. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  13. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  14. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  15. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance